About Bioline  All Journals  Testimonials  Membership  News

Iranian Journal of Pediatrics
Tehran University of Medical Sciences Press
ISSN: 1018-4406
EISSN: 1018-4406
Vol. 16, No. 3, 2006, pp. 319-324
Bioline Code: pe06043
Full paper language: Farsi
Document type: Research Article
Document available free of charge

Iranian Journal of Pediatrics, Vol. 16, No. 3, 2006, pp. 319-324

 en Evaluation of efficacy and side effects of FILGRASTIM versus PD-Grastim in prevention of neutropenia in patients with neuroblastoma under treatment with OPEC chemotherapy protocol - A Comparative Study
Abolghasemi, H; Hatami, S; Ajami, H; Ehsani, MA; Sotoudeh, K; Ordouee, M; Salamati, P & Shahgholi, E


Background: The purpose of this study was to compare the efficacy and side effects of Filgrastim (Granulocyte, Colony Stimulating Factor [G-CSF] made by Roche, Swiss) and PD-grastim (An G-CSF Analogous made by Pooyesh Daru, IRAN) on chemotherapy related neutropenia in neuroblastoma patients.
Methods: This randomized clinical trial was performed on children with Neuroblastoma. The inclusion criteria were: histopathologic proven neuroblastamo, age<16 years, Stage 3 or 4, without fever and infection, Absolute neutrophil count more than 1000/μl and platelet more than 100,000/μl and OPEC chemotherapy protocol which consists of (Oncovin, Platinium, Etoposide and Cyclophosphamide). This protocol was used every 28 days for 12 courses, in each course after chemotherapy 10µg/kg G-CSF (Filgrastim or PD-grastim) was used for 4 days. Patients were assigned randomly as odd and even numbers. Odd number patients received PD-grastim in odd courses & Filgrastim in even courses and vice versa in even number patients. Cell blood counts was taken in the beginning and in the 6, 9, 13 days of the treatment, then two times weekly until neutrophil count reached 1000 μl/dl.
Findings: Eight Neuroblastoma (6 males and 2 females) with mean Age 2.5 years were studied. Two cases were new and others were in the middle of their chemotherapy courses. Forty four cycles (Chemotherapy plus G-CSF) were studied which in 22 cycles Filgrastim and in 22 cycles PD-grastim were used. Neutropenia was found in 34 cycles. The mean time of neutropenia in Filgrastim group was 6.4±4.68 days and in PD-grastim group was 6.5±5.09 days. Among the 2 groups there was no significant difference in the incidence, intensity, and duration of neutropenia. All patients were discharged after 9 days without any complications or side effect.
Conclusion: This study shows that there are no significant differences in the efficacy and side effects of Filgrastim versus PD-grastim in prevention of neutropenia after OPEC protocol chemotherapy treatment in stage 3 & 4 neuroblastoma patients.

Neuroblastoma , Granulocyte Colony Stimulating Factor , G-CSF , Filgrastim , PDgrastim

© Copyright 2006 - TUMS PUBLICATIONS
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil